Implementing glucose control protocols in critically ill patients.
Susla
Gregory M
GM
Medical Information, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA. suslag@medimmune.com
D001786:Blood Glucose / Q000378:metabolism; D015984:Causality; D002985:Clinical Protocols; D003422:Critical Care / Q000379:methods* / Q000592:standards; D016638:Critical Illness / Q000401:mortality / Q000628:therapy*; D048909:Diabetes Complications / Q000097:blood / Q000150:complications / Q000517:prevention & control; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D019317:Evidence-Based Medicine; D018149:Glucose Intolerance / Q000150:complications / Q000517:prevention & control; D017052:Hospital Mortality; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D007003:Hypoglycemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007328:Insulin / Q000627:therapeutic use; D018579:Patient Selection
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin